VIDAS® NEPHROCLEAR Reference Interval Study

Cohort A Inclusion Criteria: * Apparently healthy adults (age ≥ 21 years); * Provide written informed consent for study (AST-017) participation Exclusion Criteria: * Any known or suspected acute illness or condition - including acute infections - at the time of enrollment or within the previous 30 days; * Any known or suspected significant new onset or chronic morbid medical condition such as: * Active cancer * Arrhythmia (atrial fibrillation, heart block, ventricular tachycardia) * Chronic coagulation abnormality * Chronic obstructive pulmonary disease (including emphysema, chronic bronchitis, and asthma) * Chronic pancreatitis * Chronic renal insufficiency * Congestive heart failure * Coronary artery disease * Diabetes mellitus (Type 1 or Type 2) * Gout * Hyper- or hypothyroidism * Hyperlipidemia (includes hypercholesterolemia) * Hypertension * Immunocompromised * Inflammatory bowel disease (including Crohn's disease and ulcerative colitis) * Liver cirrhosis * Neuromuscular disease * Peripheral vascular disease (a.k.a. peripheral artery disease) * Polycystic kidney disease * Rheumatoid arthritis * Systemic Lupus Erythematosus * Trauma-related surgery within the last 6 months; * Any surgery, hospitalization or institutionalization (such as in a nursing home) during the previous 3 months; * Received any blood product transfusion within the previous 2 months; * Pregnant women or children; * Prisoners or institutionalized individuals; * Already provided a urine sample for the AST-017 study Cohort B Inclusion Criteria: * Adults (age ≥ 21 years); * One or more of the following chronic, stable morbid conditions: * Active cancer * Arrhythmia (atrial fibrillation, heart block, ventricular tachycardia) * Chronic coagulation abnormality * Chronic obstructive pulmonary disease (including emphysema, chronic bronchitis, and asthma) * Chronic pancreatitis * Chronic renal insufficiency * Congestive heart failure * Coronary artery disease * Diabetes mellitus (Type 1 or Type 2) * Gout * Hyper- or hypothyroidism * Hyperlipidemia (includes hypercholesterolemia) * Hypertension * Immunocompromised * Inflammatory bowel disease (including Crohn's disease and ulcerative colitis) * Liver cirrhosis * Neuromuscular disease * Peripheral vascular disease (a.k.a. peripheral artery disease) * Polycystic kidney disease * Rheumatoid arthritis * Systemic Lupus Erythematosus * Provide written informed consent for study participation. * For Cohort B subjects in the AST-017 Study: * Subjects were considered to have the above condition(s) if he/she had the diagnosis by a healthcare professional and/or was under treatment by a healthcare professional for the listed condition(s). * Subjects with a condition (e.g., hypertension, hypercholesterolemia) controlled by medications were enrolled. * To be considered chronic and stable, the condition(s) must have been present for at least 1 year and without any acute change (decompensation or improvement) within the 3 months prior to enrollment. Exclusion Criteria: * Any known or suspected acute illness or condition - including acute infections - at the time of enrollment or within the previous 30 days; * Any new onset or unstable morbidities; * Trauma-related surgery within the last 6 months; * Any surgery, hospitalization or institutionalization (such as in a nursing home) during the previous 3 months; * Received any blood product transfusion within the previous 2 months; * Pregnant women or children; * Prisoners or institutionalized individuals; * Already provided a urine sample for this (AST-017) study.